AffaMed Technologies Announces the First Implantation in the China Registrational Clinical Trial of MINI WELL®, the Progressive Extended Depth-of-Focus IOL
SHANGHAI, March 3, 2023 /PRNewswire/ -- AffaMed Technologies ("AffaMed"), a joint venture established between AffaMed Therapeutics and SIFI S.p.A., today announced the completion of the first patient implantation in the Registrational Clinical Trial of its MINI WELL® progressive Extended Depth-of-Focus ("EDOF") IOL (MINI WELL®), which was conducted in the EYE & ENT Hospital of Fudan University in Shanghai,...
Neurophet to unveil new technology for analyzing ARIA side effect at ECR 2023
Introducing brain imaging analysis solutions including Neurophet AQUA and Neurophet SCALE PET Unveiling technology to analyze and monitor ARIA, side effect of anti-amyloid antibody drug for Alzheimer's disease SEOUL, South Korea, March 2, 2023 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution company for brain disease, announced its participation in the...
Porton Advanced Collaborates with DanausGT to Accelerate the Development of Gene and Cell Therapy
SUZHOU,China, March 2, 2023 /PRNewswire/ -- Porton Advanced Solutions Ltd. (Porton Advanced) and DanausGT Biotechnology Co., Ltd. (DanausGT) announced on February 27, 2023, a strategic collaboration in gene and cell therapy pipelines to expedite the development of innovative therapeutics. Porton Advanced Collaborates with DanausGT to Accelerate the Development of Gene and Cell Therapy As an end-to-end gene...
Prenetics Announces Formation of Scientific Advisory Board to Support New Business Strategy in Precision Oncology
LONDON and HONG KONG, March 2, 2023 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, is proud to announce the formation of a new Prenetics Scientific Advisory Board (the 'SAB') to provide strategic input based on their scientific knowledge and clinical expertise to help guide the further development of Prenetics' diagnostic cancer genomics...
AIRS Medical Applauded by Frost & Sullivan for Reducing MRI Equipment’s Exam Wait Times with Its SwiftMR™ Technology
SwiftMR™ improves image quality of MRI scans, enables easy installation and use, and adapts to healthcare providers' existing scanners because it is a stand-alone offering. SAN ANTONIO, March 2, 2023 /PRNewswire/ -- Recently, Frost & Sullivan researched the artificial intelligence (AI)-powered magnetic resonance imaging (MRI) reconstruction solution industry and, based on its findings,...
Abbisko Therapeutics Announces an Out-License Agreement with Allist for ABK3376
SHANG HAI, March 2, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that it has entered into an exclusive Out-License Agreement (the "Agreement" hereafter) with Shanghai Allist Pharmaceuticals Co., Ltd., ("Allist" hereafter) for the further development, manufacture, use, and sales of (EGFR-TKI) ABK3376 in China (Mainland China, Hong...
Sanyou Biopharmaceuticals opens Cambridge MA, US office, expanding its business outreach to a central hub of biotech network
CAMBRIDGE, Mass., March 2, 2023 /PRNewswire/ -- Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is opening a new office in Cambridge Innovation Centre, CIC, marking a new era towards the company's rising ambition on serving and collaborating with world's best biotech start-ups and ventures. Plans to develop operations in great Boston area were expedited by the recruitment...
111 to Announce Fourth Quarter and Fiscal Year 2022 Unaudited Financial Results- Conference Call to Follow
SHANGHAI, March 2, 2023 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced that it will report its unaudited financial results for the fourth quarter and fiscal year 2022 ended December 31, 2022, before the U.S. market opens on Thursday, March...
ExoCoBio obtained 2 GMP Licenses for Exosome Biopharmaceuticals from Korea MFDS and for Hyaluronic Acid (HA) Dermal Fillers from Brazil ANVISA
ExoGMP™ is the world's largest exosome manufacturing facility in Osong, South Korea. Cellosome™ HA fillers are expected to be approved in 2023. ExoCoBio has all 3 types of GMP clearance for pharmaceuticals, medical devices, & cosmetics. SEOUL, South Korea, March 2, 2023 /PRNewswire/ -- ExoCoBio Inc. announced that it obtained the "Certificate of Advanced Biopharmaceutical Manufacturing"...
DEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY
Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor LAUSANNE, Switzerland, March 2, 2023 /PRNewswire/ -- Debiopharm (www.debiopharm.com), an independent Swiss-based, biopharmaceutical company aiming to develop tomorrow's standard-of-care treatments to cure cancer and infectious diseases, today announced having obtained the global rights for FT-3171, a small molecule USP1 inhibitor program targeting...
